Other publications - Fiona Thistlethwaite

Articles

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

Toni K Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David McDermott, Paul B Robbins, David D Chism, Daniel Cho, Michael B Atkins, Michael S Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Camilla Fowst, Alessandra di Pietro, Brian I Rini

Lancet Oncology 2018 (Published online 8 March 2018)


The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE

Cancer Immunol Immunother 2017 (Published online Jun 2017)


High-Dose Interleukin 2 – A 10 year single - site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives excellent outcome

S Chow, V Galvis, M Pillai, R Leach, E Keene, A Spencer-Shaw, A Shablak, J Shank, Liptrot T, F Thistlethwaite, R Hawkins

J Immunother Cancer 4(67) 2016 (published online Oct 2016)

 

Book chapters

Cellular therapy of cancer: Development of gene therapy based approaches (Editor RE Hawkins); Chapter 6: Clinical Trial Design; Robert E Hawkins, John Haanen, Fiona Thistlethwaite; World scientific publishing company (2014) ISBN 978 981 4295 13 0


Treatment of Cancer 5th Edition. Edited by P Price, K Sikora and T Illidge. Chapter 9: Biological Therapies: Cytokines and Adoptive Cell Therapy; FC Thistlethwaite, PL Stern, RE Hawkins; Edward Arnold (Publishers) Ltd. (2008) ISBN 13 978 0 340 912218

;